MedPath

Lumateperone

Generic Name
Lumateperone
Brand Names
Caplyta
Drug Type
Small Molecule
Chemical Formula
C24H28FN3O
CAS Number
313368-91-1
Unique Ingredient Identifier
70BSQ12069
Background

Schizophrenia is a complex mental illness and impacts approximately 1% of the population. Although there are several antipsychotics including aripiprazole, paliperidone and clozapine available for clinical use, they are generally accompanied by significant metabolic and/or neurological adverse effects.

Lumateperone is a newly approved 2nd generation antipsychotic currently indicated for the treatment of schizophrenia. It has a unique receptor binding profile and differs from other antipsychotics in that it modulates glutamate, serotonin and dopamine, which are all neurotransmitters that contribute to the pathophysiology of schizophrenia.

The data so far indicates that lumateperone can alleviate both positive and negative symptoms of schizophrenia. Further, not only is the new antipsychotic selective for dopamine (D2) receptors in the mesolimbic and mesocortical brain regions, but it also has minimal off-target activity. Both characteristics lend to a more favourable adverse effect profile and ultimately safer drug.

Indication

Lumateperone is approved for the treatment of schizophrenia in adults. It is also approved for the treatment of depressive episodes associated with bipolar disorder (i.e. bipolar depression) in adults, as monotherapy and/or adjunctive therapy with lithium or valproate.

Associated Conditions
Depressive Episodes, Schizophrenia
Associated Therapies
-
Clinical Trials
Related News
finance.yahoo.com
·

Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results

Axsome Therapeutics released data from Alzheimer's studies showing AXS-05 significantly delayed agitation relapse in ACCORD-2 but not in ADVANCE-2. AXS-05 was safe and well-tolerated, with no increased risk of falls or cognitive decline. Axsome plans to submit an NDA to the FDA in 2025. Analyst sees hope despite mixed results, citing precedents of drug approvals with similar trial outcomes.
media.market.us
·

Antidepressants Drugs Market Towards US$ 30.5 Billion By 2033

The global antidepressants drugs market is projected to grow from US$ 13.8 billion in 2023 to US$ 30.5 billion by 2033, driven by rising mental health disorders, increased awareness, and advancements in treatment options. North America led in 2023 with a 35.3% share. Challenges include side effects and variability in drug efficacy. Recent advancements include new antidepressants with fewer side effects and ongoing research into innovative treatments.
uk.investing.com
·

Avidity Biosciences shares initiated with Buy on establishment

H.C. Wainwright rates Avidity Biosciences (NASDAQ:RNA) as Buy with a $72 target, citing its AOC platform's success and three clinical programs. Avidity's DM1, FSHD, and DMD programs show promising safety and efficacy, with potential for accelerated approvals. The company, valued at $3.7B, plans pipeline expansion and expects 2025 updates. Recent financials and FDA's lift on del-desiran's hold bolster its position.
law.com
·

Litigation Surge: Drugmakers Launch Flood of Suits to Halt Generics

Law Offices of Gary Martin Hays & Associates, P.C. contact: (470) 294-1674. Law Offices of Mark E. Salomone contact: (857) 444-6468.
hcplive.com
·

Psychiatry Month in Review: November 2024

Intra-Cellular Therapies submitted an sNDA to the FDA for lumateperone as an adjunctive therapy for MDD, with phase 3 studies showing significant symptom reduction. Supernus Pharmaceuticals presented phase 2a data on SPN-820, showing rapid depressive symptom reduction and decreased suicidal ideation. Teva announced phase 3 SOLARIS study results showing TEV-749 improved social functioning in schizophrenia patients. Intra-Cellular Therapies also reported lumateperone delayed relapse in schizophrenia patients. However, emraclidine did not show significant symptom reduction in phase 2 trials. A study found high-dose antipsychotic use increased mortality risk in schizophrenia patients, while high-dose antidepressants reduced it.
psychiatrictimes.com
·

sNDA Submitted: Lumateperone as Adjunctive Therapy for Major Depressive Disorder

Intra-Cellular Therapies submitted an sNDA to the FDA for lumateperone (Caplyta) as adjunctive therapy for MDD in adults. Studies 501 and 502 showed Caplyta's efficacy and safety profile, with robust efficacy for MDD and favorable metabolic, weight, and movement disorder profiles.
globenewswire.com
·

Intra-Cellular Therapies Submits Supplemental New Drug

Intra-Cellular Therapies submits sNDA to FDA for CAPLYTA as adjunctive therapy for MDD, based on positive results from Studies 501 and 502, showing robust efficacy and favorable safety profile. CAPLYTA, if approved, would treat over 30 million adult patients in the US for three major psychiatry indications.
managedhealthcareexecutive.com
·

Intra-Cellular Therapies Seeks FDA Approval for CAPLYTA as Additional Treatment for Depression

Intra-Cellular Therapies submits supplemental New Drug Application to FDA for Caplyta as MDD treatment. Caplyta, an oral atypical antipsychotic, is currently approved for schizophrenia and bipolar disorder. Phase 3 trials showed significant improvement in depression symptoms for non-responders to other antidepressants. Common side effects are similar to placebo, with low rates of movement problems and minimal metabolic changes. Caplyta's market presence is growing, with net product sales increasing by 86% in 2023.
biospace.com
·

Intra-Cellular Eyes Depression Approval for Caplyta as Stock Flies Under the Radar

Intra-Cellular Therapies seeks FDA approval for Caplyta as an adjunct treatment for major depressive disorder (MDD), potentially expanding its market to over $1 billion. Caplyta, already approved for schizophrenia and bipolar disorder, saw Q3 sales of $175 million, with Q4 projections at least $193 million. The MDD submission is based on Phase III trials showing symptom improvement when paired with an antidepressant. Jefferies estimates a 90–95% approval likelihood, predicting a company valuation of $9–12 billion. Intra-Cellular is also exploring Caplyta for autism and developing ITI-214 for Parkinson’s and ITI-333 for opioid use.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy